Results 61 to 70 of about 19,437 (169)

Use of octreotide for the treatment of protein‐losing enteropathy in dogs: Retrospective study of 18 cases

Journal of Veterinary Internal Medicine
Background More than 50% of dogs with protein‐losing enteropathy (PLE) fail to respond to standard therapies. Octreotide, a somatostatin analogue, is used in cases of intestinal lymphangiectasia (IL) in humans with some success.
Sara A. Jablonski, Allison S. W. Mazepa, M. Katherine Tolbert   +2 more
doaj   +1 more source

Octreotide (somatostatin analog) attenuates cardiac ischemia/reperfusion injury via activating nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling pathway in rat model of hyperthyroidism

Future Journal of Pharmaceutical Sciences, 2020
Background Hyperthyroidism is known to increase the risk of ischemic heart diseases. Octreotide has been reported to attenuate ischemia/reperfusion (I/R) injury.
Randa Salah Gomaa, Nevertyty Mohamed Mahmoud, Nourelhuda Abdelaziz Mohammed   +2 more
doaj   +1 more source

Five Advances in the Last 50 Years That Have Impacted Endocrine Surgery

World Journal of Surgery, EarlyView.
Matilda Anneback, Priya H. Dedhia, Aimee Di Marco, Els Nieveen van Dijkum, Julie A. Miller, Janice L. Pasieka   +5 more
wiley   +1 more source

Metastatic Unfunctional Pancreatic Neuroendocrine Tumor in Lynch Syndrome

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Lynch syndrome (LS), a well‐known cancer risk syndrome, is caused by deleterious germline mutations in the mismatch repair genes. LS predispose patients to various types of cancers including colon adenocarcinoma. We discuss the case of a woman with LS who also developed a non‐functioning pancreatic neuroendocrine tumor (P‐NET) following ...
Fateme Salemi, Zahra Sadin, Atefe Barzegari, Seyed Mohammad Reza Mortazavizadeh, Massih Bahar, Motahare Amiri   +5 more
wiley   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, EarlyView.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

Clinical Utility of 68Ga‐DOTATOC Positron Emission Tomography/Computed Tomography in Evaluating Metastatic Lesions of Clear Cell Renal Cell Carcinoma: A Case Report

IJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction 68Ga‐DOTATOC positron emission tomography/computed tomography (PET/CT) targets somatostatin receptors (SSTRs) and is an established molecular imaging modality for neuroendocrine tumors (NETs). Although SSTR expression has been reported in renal cell carcinoma (RCC), its clinical utility remains unclear. Case Presentation A 76‐year‐
Yuta Mine, Toru Sakatani, Sho Koyasu, Takashi Ogata, Yuki Teramoto, Akio Sakamoto, Takashi Mizowaki, Yuji Nakamoto, Takashi Kobayashi, Takayuki Goto   +9 more
wiley   +1 more source

Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases

Scientific Reports
Lanreotide and Octreotide are used to treat various endocrine and neoplastic diseases. This study aims to compare the adverse event profiles of Lanreotide and Octreotide in somatostatin-responsive diseases using FAERS data.
Le Wang, Shenglin Chen, Mengying Wu, Lijuan Zhou   +3 more
doaj   +1 more source

Summative Comorbidities Are Independently Associated With Mortality in Patients With Hepatocellular Carcinoma

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background Comorbidities might limit therapeutic options and negatively impact survival in patients with hepatocellular carcinoma (HCC). The Charlson Comorbidity Index (CCI) is widely used to summarize and quantify comorbidities. Methods HCC patients diagnosed between 1992 and 2018 at the Medical University of Vienna were retrospectively ...
Tobias Meischl, Moritz Steurer, Lorenz Balcar, Yannick Marcour, Patrick Meier, Lukas Bucher, Ye‐Rin Park, Katharina Pomej, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Bernhard Scheiner, Matthias Pinter   +12 more
wiley   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing’s Syndrome

Case Reports in Endocrinology, 2016
A 30-year-old Caucasian man presented with severe Cushing’s syndrome (CS) resulting from ectopic adrenocorticotropin syndrome (EAS) from a metastatic pancreatic neuroendocrine tumor.
Andreas G. Moraitis, Richard J. Auchus
doaj   +1 more source